NCT05932745

Brief Summary

This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
66

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 6, 2023

Completed
2 years until next milestone

Study Start

First participant enrolled

June 20, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

December 26, 2025

Status Verified

December 1, 2025

Enrollment Period

11 months

First QC Date

June 28, 2023

Last Update Submit

December 23, 2025

Conditions

Keywords

Menthol, cooling components, cigarette, e-cigarette, vaping

Outcome Measures

Primary Outcomes (3)

  • Liking: Score change in liking/wanting of each e-cigarette condition (5 conditions in total)

    The Labeled Hedonic Scale will be used to ask about liking and wanting of the e-cigarette (one item Visual Analog Scale with ratings ranging from "most disliked sensation imaginable" to "most liked sensation imaginable" with higher values indicating greater liking).

    Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)

  • Reinforcing Efficacy: Score change in drug effects of each e-cigarette condition (5 conditions in total)

    Difference between e-cigarette effects for each e-cigarette condition as measured by the computerized version of the Drug Effects Questionnaire (DEQ). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. A modified version of the Drug Effects Questionnaire (DEQ) will be used in which participants rate acute responses to the e-cigarette on a 0-100mm scale from "not at all" (0mm) to "extremely" (100mm).

    Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)

  • Irritation/Harshness: Score change in irritation of harshness of each e-cigarette condition (5 conditions in total)

    Difference in irritation at each e-cigarette condition as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).

    Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)

Secondary Outcomes (2)

  • Craving: Change in craving score for e-cigarette from baseline at each e-cigarette condition (5 conditions in total)

    At baseline (at 0 minute), following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)

  • Changes of salivary Nicotine and Cotinine Levels from baseline at each e-cigarette condition (6 conditions in total)

    At baseline (at 0 minute), Following administration of e-cigarette condition 1 (at 10 minutes), following administration of e-cigarette condition 2 (at 40 minutes)...following administration of e-cigarette condition 6 (at 160 minutes)

Study Arms (18)

Non-menthol, nicotine 59mg/ml (1)

EXPERIMENTAL

Flavor without menthol with 59mg/ml nicotine

Other: E-liquid coolant (No WS-3) for non-menthol (1)

Low (0.1%) menthol, nicotine 59mg/ml (1)

EXPERIMENTAL

Flavor with low menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (No WS-3) for low (0.1%) menthol (1)

High (2.0%) menthol, nicotine 59mg/ml (1)

EXPERIMENTAL

Flavor with high menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (No WS-3) for high (2.0%) menthol (1)

Non-menthol, nicotine 59mg/ml (2)

EXPERIMENTAL

Flavor without menthol with 59mg/ml nicotine

Other: E-liquid coolant (Low [0.1%] WS-3) for non-menthol (2)

Low (0.1%) menthol, nicotine 59mg/ml (2)

EXPERIMENTAL

Flavor with low menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (Low [0.1%] WS-3) for low (0.1%) menthol (2)

High (2.0%) menthol, nicotine 59mg/ml (2)

EXPERIMENTAL

Flavor with high menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (Low [0.1%] WS-3) for high (2.0%) menthol (2)

Non-menthol, nicotine 59mg/ml (3)

EXPERIMENTAL

Flavor without menthol with 59mg/ml nicotine

Other: E-liquid coolant (High [2.0%] WS-3) for non-menthol (3)

Low (0.1%) menthol, nicotine 59mg/ml (3)

EXPERIMENTAL

Flavor with low menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (High [2.0%] WS-3) for low (0.1%) menthol (3)

High (2.0%) menthol, nicotine 59mg/ml (3)

EXPERIMENTAL

Flavor with high menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (High [2.0%] WS-3) for high (2.0%) menthol (3)

Non-menthol, nicotine 59mg/ml (4)

EXPERIMENTAL

Flavor without menthol with 59mg/ml nicotine

Other: E-liquid coolant (Low [0.1%] WS-23) for non-menthol (4)

Low (0.1%) menthol, nicotine 59mg/ml (4)

EXPERIMENTAL

Flavor low menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (Low [0.1%] WS-23) for low (0.1%) menthol (4)

High (2.0%) menthol, nicotine 59mg/ml (4)

EXPERIMENTAL

Flavor high menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (Low [0.1%] WS-23) for high (2.0%) menthol (4)

Non-menthol, nicotine 59mg/ml (5)

EXPERIMENTAL

Flavor without menthol with 59mg/ml nicotine

Other: E-liquid coolant (High [2.0%] WS-23) for non-menthol (5)

Low (0.1%) menthol, nicotine 59mg/ml (5)

EXPERIMENTAL

Flavor low menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (High [2.0%] WS-23) for low (0.1%) menthol (5)

High (2.0%) menthol, nicotine 59mg/ml (5)

EXPERIMENTAL

Flavor high menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (High [2.0%] WS-23) for high (2.0%) menthol (5)

Non-menthol, nicotine 59mg/ml (6)

EXPERIMENTAL

Flavor without menthol with 59mg/ml nicotine

Other: E-liquid coolant (4% WS-23) for non-menthol (6)

Low (0.1%) menthol, nicotine 59mg/ml (6)

EXPERIMENTAL

Flavor low menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (4% WS-23) for low (0.1%) menthol (6)

High (2.0%) menthol, nicotine 59mg/ml (6)

EXPERIMENTAL

Flavor high menthol concentration with 59mg/ml nicotine

Other: E-liquid coolant (4% WS-23) for high (2.0%) menthol (6)

Interventions

Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.

Also known as: Flavor type
Non-menthol, nicotine 59mg/ml (1)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.

Also known as: Flavor type
Low (0.1%) menthol, nicotine 59mg/ml (1)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants without WS-3.

Also known as: Flavor type
High (2.0%) menthol, nicotine 59mg/ml (1)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.

Also known as: Flavor type
Non-menthol, nicotine 59mg/ml (2)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.

Also known as: Flavor type
Low (0.1%) menthol, nicotine 59mg/ml (2)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-3 concentration.

Also known as: Flavor type
High (2.0%) menthol, nicotine 59mg/ml (2)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.

Also known as: Flavor type
Non-menthol, nicotine 59mg/ml (3)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.

Also known as: Flavor type
Low (0.1%) menthol, nicotine 59mg/ml (3)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-3 concentration.

Also known as: Flavor type
High (2.0%) menthol, nicotine 59mg/ml (3)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.

Also known as: Flavor type
Non-menthol, nicotine 59mg/ml (4)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.

Also known as: Flavor type
Low (0.1%) menthol, nicotine 59mg/ml (4)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with low WS-23 concentration.

Also known as: Flavor type
High (2.0%) menthol, nicotine 59mg/ml (4)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.

Also known as: Flavor type
Non-menthol, nicotine 59mg/ml (5)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.

Also known as: Flavor type
Low (0.1%) menthol, nicotine 59mg/ml (5)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with high WS-23 concentration.

Also known as: Flavor type
High (2.0%) menthol, nicotine 59mg/ml (5)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.

Non-menthol, nicotine 59mg/ml (6)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.

Low (0.1%) menthol, nicotine 59mg/ml (6)

Adult users of e-cigarette will be exposed to distinct e-liquid coolants with 4% WS-23 concentration.

High (2.0%) menthol, nicotine 59mg/ml (6)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • Able to read and write
  • Some current e-cigarette use
  • Urine cotinine ≥200ng/ml
  • Willing to abstain from tobacco/nicotine use 2 hours prior to sessions

You may not qualify if:

  • Current use of non-prescription substances besides nicotine, marijuana, alcohol
  • Any significant current medical or psychiatric condition
  • Known hypersensitivity to propylene glycol
  • Pregnant or lactating females
  • Uncontrolled asthma
  • Nut/e-liquid flavorant allergy
  • Current marijuana (tetrahydrocannabinol) vaping + E-cigarette or vaping use Associated Lung Injury (EVALI) symptoms
  • Dislike of menthol flavor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

JB Pierce Lab

New Haven, Connecticut, 06519, United States

RECRUITING

Related Publications (1)

  • Lim J, Wood A, Green BG. Derivation and evaluation of a labeled hedonic scale. Chem Senses. 2009 Nov;34(9):739-51. doi: 10.1093/chemse/bjp054.

    PMID: 19833660BACKGROUND

MeSH Terms

Conditions

Tobacco Use DisorderVaping

Interventions

Menthol

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental DisordersSmokingBehavior

Intervention Hierarchy (Ancestors)

CyclohexanolsHexanolsFatty AlcoholsAlcoholsOrganic ChemicalsCyclohexane MonoterpenesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsMonoterpenesTerpenesLipids

Study Officials

  • Suchitra Krishnan-Sarin, PhD

    Yale University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Danielle Davis, PhD

CONTACT

Wei Li, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
Participants will be given a nicotine containing e-cigarette that could have various levels of cooling flavoring. Participants will not be told the nicotine concentration of the product or the type or concentration of the added coolant or what order it is presented in. Investigator and research assistant (i.e. care provider) will know the doses of nicotine and coolant, but will not know what order coolants are presented to participants.
Purpose
OTHER
Intervention Model
CROSSOVER
Model Details: All participants receive all 18 study conditions.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 28, 2023

First Posted

July 6, 2023

Study Start

June 20, 2025

Primary Completion

May 1, 2026

Study Completion

May 1, 2026

Last Updated

December 26, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

We may share information about the IPD and study results with other researchers in the future, but the information will be de-identified.

Shared Documents
STUDY PROTOCOL, ANALYTIC CODE
Time Frame
The identifiable information will be kept for 7 years. After that, the data will become anonymous.
Access Criteria
The de-identified data will be made available for research purposes by contacting the PI.

Locations